14% . NURO +13% . PBPB +12% . CALL +9% . SINA +9% . M +7% . Top 10 Losers: MTL -30% . CDXS -27% . YRCW -27% . TELK -20% . SNTA -12% . SB -11% . CHTP -9% . GILT -9% . BAGL -6% . BALT -5% . Post your comment!
By EnhydrisPECorp : Editors' Note: This article discusses micro-cap stocks. Please be aware of the risks associated with these stocks. Yesterday I wrote an article calling Sarepta ( SRPT ) a short due to problems inherent in their lead drug candidate and the design of its Phase II clinical trials.
By EnhydrisPECorp : Shares of Telik Inc ( TELK ) jumped an astounding 105% last Friday upon the announcement ..... lineages (red blood cells, white blood cells or platelets). Telik 's drug candidate Telintra is an inhibitor of the enzyme glutathione
We are dropping coverage of Telik TELK to focus our resources elsewhere.
Although Telik 's TELK workforce reduction activities helped narrow ..... cash) sunk to $57.3 million. The fate of Telik 's former frontrunner Telcyta, which flopped ..... we think an extreme amount of risk surrounds Telik 's future.
After Telik TELK unveiled its companywide reorganization ..... the firm is a speculative investment. Telik is paring down its drug-discovery team ..... With resources focused on Telintra, Telik seems to be pushing former lead drug candidate
fair value uncertainty rating for Telik TELK to extreme from very high in light ..... horizon, and a shrinking cash supply, Telik will need to issue many shares next year just to survive. As Telik 's stock price plummets, we think
We're putting Telik TELK under review to take another look at our assumptions, in light of the stock's recent poor performance. We'll publish an updated report shortly.
We're putting Telik TELK under review as we transfer coverage to a new analyst. We will publish an updated report as soon as possible.
Telik TELK has announced that it is free to resume ..... approval a long shot. We're skeptical that Telik will be able to improve its management of ..... to enroll any new trials. That said, if Telik is able to demonstrate that Telcyta is effective